| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Violette Shelia M. | Chief Scientific Officer | Q32 BIO INC., 830 WINTER STREET, WALTHAM | /s/ Eric Bell, Attorney-in-Fact | 28 Aug 2025 | 0002016144 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | QTTB | Common Stock | Sale | $5,385 | -2,990 | -4.9% | $1.80 | 58,384 | 26 Aug 2025 | Direct | F1, F2 |
| holding | QTTB | Common Stock | 36,277 | 26 Aug 2025 | By Violette Holdings LLC | F3 |
| Id | Content |
|---|---|
| F1 | Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. |
| F2 | The price reported is a weighted average price. The securities were sold in multiple transactions over two consecutive trading days, at per share prices ranging from $1.81 to $1.96 and $1.73 to $1.83, respectively. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote 2. |
| F3 | Shares held by Violette Holdings LLC ("Violette Holdings"). The Reporting Person is a manager of Violette Holdings and disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose. |